世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
医薬品、バイオテクノロジー、診断薬における共同開発提携条件と契約の世界市場インサイト、2029年までの予測Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Insights, Forecast to 2029 共同開発パートナーとの提携により、当事者は価 値を確保しリスクを軽減することができるが、製 品が市場に出た場合の潜在的なアップサイドの一部を 保持することができる。ライセンサーがプロジェク トを商業化... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー共同開発パートナーとの提携により、当事者は価 値を確保しリスクを軽減することができるが、製 品が市場に出た場合の潜在的なアップサイドの一部を 保持することができる。ライセンサーがプロジェク トを商業化しなかった場合、ライセンシー・パート ナーまたは別のパートナーに、より早い段階のライセ ンス契約よりも高い金額で権利を売却することができ る。市場分析と洞察製薬、バイオテクノロジー、診断薬市場における世界の共同開発提携条件と契約 医薬品、バイオテクノロジー、診断薬における共同開発提携条件と契約の世界市場は、2022年の100万米ドルに比べ、2023年にはプラス成長で100万米ドルに達すると予測される。川下産業からの需要の増加を背景に、医薬品、バイオテクノロジー、診断薬業界における共同開発提携条件と契約は、2029年には百万米ドルに達すると評価されている。2023年から2029年までのCAGRは％である。 世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5％で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。 レポートの対象 本レポートは、2018年から2029年までの世界の製薬・バイオテクノロジー・診断薬における共同開発提携条件と契約市場の概要を紹介し、読者が世界の製薬・バイオテクノロジー・診断薬における共同開発提携条件と契約市場を多角的に包括的に理解することを目的としています。2018年から2029年までの地域別収益、2018年から2023年までの企業の収益と粗利益率などの項目を分析しています。さらに、2018年から2029年までの各地域の製品タイプおよびアプリケーションの収益も取り上げています。 レポートに掲載されている企業、タイプ、アプリケーション、地域 企業別 1STバイオセラピューティクス 3Bファーマシューティカルズ 3Dマイクロマック 3DMed 3Dシステムズ 10X ジェノミクス A*STAR 科学技術庁 科学技術研究庁 A*STARマイクロエレクトロニクス研究所（IME） A2Aファーマシューティカルズ アッヴィ アブセラ ABLバイオ アブプロ 軍医科学アカデミー（中国） アクセリックス アコードヘルスケア アキュジェノミクス ACEAバイオサイエンシズ ACイミューン アコースティック・メドシステムズ アダプティミューン アドゥロ・バイオテック アドバクシス アドベンタス・ベンチャーズ エアロラーゼ タイプ別セグメント 資産購入 譲渡 共同開発 共同マーケティング 共同販促 共同研究開発 契約サービス CRADA クロスライセンス その他 用途別セグメント 産業分野 治療分野 技術タイプ 契約内容 財務条件 開発段階 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア 北欧諸国 その他の欧州諸国 中国 アジア（中国を除く） 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ、中東、アフリカ ブラジル メキシコ トルコ イスラエル GCC諸国 章の概要 第1章：製品の定義、タイプ、用途の紹介 第2章 2018年から2029年までの地域別収益分析 第3章：製品名企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報などの詳細分析 第4章 2018年から2029年までの世界のタイプ別製品収益分析 第5章 世界の2018年から2029年までの用途別製品収益分析 第6章：2018年から2029年までの米国・カナダのタイプ別・用途別製品収益分析2018年から2029年までの米国＆カナダにおける各国の製品収益分析 第7章：欧州における2018年から2029年までのタイプ別および用途別製品収益分析。2018年から2029年までの欧州における各国の製品収益分析 第8章：2018年から2029年までの中国のタイプ別および用途別製品収益分析。2018年から2029年までの中国の製品収益分析 第9章：2018年から2029年までのアジア（中国を除く）のタイプ別・用途別製品収益分析。2018年から2029年までのアジア（中国を除く）の各国の製品収益分析 第10章：2018年から2029年までの中東、アフリカ、ラテンアメリカにおけるタイプ別および用途別の製品収益分析。2018年から2029年までの中東、アフリカ、ラテンアメリカにおける各国の製品収益分析。 第11章：企業概要：企業の基本情報、主要事業、製薬・バイオテクノロジー・診断薬紹介における共同開発提携条件と契約などを網羅。2018年から2023年までの製薬、バイオテクノロジー、診断薬における共同開発提携条件と契約 各社の売上高とグロスマージン 第12章：製薬、バイオテクノロジー、診断薬における共同開発提携条件と契約に関するQYResearchの結論 第13章：QYResearchが採用した方法論とデータソース 目次1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Asset purchase 1.2.3 Assignment 1.2.4 Co-development 1.2.5 Co-market 1.2.6 Co-promotion 1.2.7 Collaborative R&D 1.2.8 Contract service 1.2.9 CRADA 1.2.10 Cross-licensing 1.2.11 Others 1.3 Market by Application 1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Industry sector 1.3.3 Therapy areas 1.3.4 Technology type 1.3.5 Deal components 1.3.6 Financial terms 1.3.7 Stage of development 1.3.8 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2018-2029) 2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region 2.2.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2018-2023) 2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2024-2029) 2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics 2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends 2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers 2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges 2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Players 3.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2018-2023) 3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2018-2023) 3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio 3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2022 3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served 3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application 3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type 4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2018-2023) 4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2024-2029) 5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application 5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2018-2023) 5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 6.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 6.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 6.2.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 6.3.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 6.3.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 6.3.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 6.4.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 6.4.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 7.2.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 7.2.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 7.2.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 7.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 7.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 7.3.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 7.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 7.4.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 8.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 8.2.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 8.2.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 8.2.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 8.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 8.3.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 8.3.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 8.3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 9.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 9.2.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 9.2.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 9.2.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 9.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 9.3.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 9.3.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 9.3.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 9.4 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region 9.4.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2018-2023) 9.4.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 10.2.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 10.3.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 10.4.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 1ST Biotherapeutics 11.1.1 1ST Biotherapeutics Company Details 11.1.2 1ST Biotherapeutics Business Overview 11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.1.5 1ST Biotherapeutics Recent Developments 11.2 3B Pharmaceuticals 11.2.1 3B Pharmaceuticals Company Details 11.2.2 3B Pharmaceuticals Business Overview 11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.2.5 3B Pharmaceuticals Recent Developments 11.3 3D-Micromac 11.3.1 3D-Micromac Company Details 11.3.2 3D-Micromac Business Overview 11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.3.5 3D-Micromac Recent Developments 11.4 3DMed 11.4.1 3DMed Company Details 11.4.2 3DMed Business Overview 11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.4.5 3DMed Recent Developments 11.5 3D Systems 11.5.1 3D Systems Company Details 11.5.2 3D Systems Business Overview 11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.5.5 3D Systems Recent Developments 11.6 10X Genomics 11.6.1 10X Genomics Company Details 11.6.2 10X Genomics Business Overview 11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.6.5 10X Genomics Recent Developments 11.7 A*STAR Agency for Science 11.7.1 A*STAR Agency for Science Company Details 11.7.2 A*STAR Agency for Science Business Overview 11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.7.5 A*STAR Agency for Science Recent Developments 11.8 Technology and Research 11.8.1 Technology and Research Company Details 11.8.2 Technology and Research Business Overview 11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.8.5 Technology and Research Recent Developments 11.9 A*STAR Institute of Microelectronics (IME) 11.9.1 A*STAR Institute of Microelectronics (IME) Company Details 11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview 11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments 11.10 A2A Pharmaceuticals 11.10.1 A2A Pharmaceuticals Company Details 11.10.2 A2A Pharmaceuticals Business Overview 11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.10.5 A2A Pharmaceuticals Recent Developments 11.11 Abbvie 11.11.1 Abbvie Company Details 11.11.2 Abbvie Business Overview 11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.11.5 Abbvie Recent Developments 11.12 AbCellera 11.12.1 AbCellera Company Details 11.12.2 AbCellera Business Overview 11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.12.5 AbCellera Recent Developments 11.13 ABL Bio 11.13.1 ABL Bio Company Details 11.13.2 ABL Bio Business Overview 11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.13.5 ABL Bio Recent Developments 11.14 Abpro 11.14.1 Abpro Company Details 11.14.2 Abpro Business Overview 11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.14.5 Abpro Recent Developments 11.15 Academy of Military Medical Sciences (China) 11.15.1 Academy of Military Medical Sciences (China) Company Details 11.15.2 Academy of Military Medical Sciences (China) Business Overview 11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.15.5 Academy of Military Medical Sciences (China) Recent Developments 11.16 Accellix 11.16.1 Accellix Company Details 11.16.2 Accellix Business Overview 11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.16.5 Accellix Recent Developments 11.17 Accord Healthcare 11.17.1 Accord Healthcare Company Details 11.17.2 Accord Healthcare Business Overview 11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.17.5 Accord Healthcare Recent Developments 11.18 AccuGenomics 11.18.1 AccuGenomics Company Details 11.18.2 AccuGenomics Business Overview 11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.18.5 AccuGenomics Recent Developments 11.19 ACEA Biosciences 11.19.1 ACEA Biosciences Company Details 11.19.2 ACEA Biosciences Business Overview 11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.19.5 ACEA Biosciences Recent Developments 11.20 AC Immune 11.20.1 AC Immune Company Details 11.20.2 AC Immune Business Overview 11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.20.5 AC Immune Recent Developments 11.21 Acoustic MedSystems 11.21.1 Acoustic MedSystems Company Details 11.21.2 Acoustic MedSystems Business Overview 11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.21.5 Acoustic MedSystems Recent Developments 11.22 Adaptimmune 11.22.1 Adaptimmune Company Details 11.22.2 Adaptimmune Business Overview 11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.22.5 Adaptimmune Recent Developments 11.23 Aduro BioTech 11.23.1 Aduro BioTech Company Details 11.23.2 Aduro BioTech Business Overview 11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.23.5 Aduro BioTech Recent Developments 11.24 Advaxis 11.24.1 Advaxis Company Details 11.24.2 Advaxis Business Overview 11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.24.5 Advaxis Recent Developments 11.25 Adventus Ventures 11.25.1 Adventus Ventures Company Details 11.25.2 Adventus Ventures Business Overview 11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.25.5 Adventus Ventures Recent Developments 11.26 Aerolase 11.26.1 Aerolase Company Details 11.26.2 Aerolase Business Overview 11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.26.5 Aerolase Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
SummaryCo-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal. Table of Contents1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Asset purchase 1.2.3 Assignment 1.2.4 Co-development 1.2.5 Co-market 1.2.6 Co-promotion 1.2.7 Collaborative R&D 1.2.8 Contract service 1.2.9 CRADA 1.2.10 Cross-licensing 1.2.11 Others 1.3 Market by Application 1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Industry sector 1.3.3 Therapy areas 1.3.4 Technology type 1.3.5 Deal components 1.3.6 Financial terms 1.3.7 Stage of development 1.3.8 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2018-2029) 2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region 2.2.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2018-2023) 2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2024-2029) 2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics 2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends 2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers 2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges 2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Players 3.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2018-2023) 3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2018-2023) 3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio 3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2022 3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served 3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application 3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type 4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2018-2023) 4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2024-2029) 5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application 5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2018-2023) 5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 6.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 6.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 6.2.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 6.3.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 6.3.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 6.3.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 6.4.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 6.4.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 7.2.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 7.2.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 7.2.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 7.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 7.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 7.3.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 7.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 7.4.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 8.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 8.2.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 8.2.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 8.2.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 8.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 8.3.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 8.3.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 8.3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 9.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 9.2.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 9.2.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 9.2.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 9.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 9.3.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 9.3.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 9.3.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 9.4 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region 9.4.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2018-2023) 9.4.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type 10.2.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application 10.3.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country 10.4.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 1ST Biotherapeutics 11.1.1 1ST Biotherapeutics Company Details 11.1.2 1ST Biotherapeutics Business Overview 11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.1.5 1ST Biotherapeutics Recent Developments 11.2 3B Pharmaceuticals 11.2.1 3B Pharmaceuticals Company Details 11.2.2 3B Pharmaceuticals Business Overview 11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.2.5 3B Pharmaceuticals Recent Developments 11.3 3D-Micromac 11.3.1 3D-Micromac Company Details 11.3.2 3D-Micromac Business Overview 11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.3.5 3D-Micromac Recent Developments 11.4 3DMed 11.4.1 3DMed Company Details 11.4.2 3DMed Business Overview 11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.4.5 3DMed Recent Developments 11.5 3D Systems 11.5.1 3D Systems Company Details 11.5.2 3D Systems Business Overview 11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.5.5 3D Systems Recent Developments 11.6 10X Genomics 11.6.1 10X Genomics Company Details 11.6.2 10X Genomics Business Overview 11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.6.5 10X Genomics Recent Developments 11.7 A*STAR Agency for Science 11.7.1 A*STAR Agency for Science Company Details 11.7.2 A*STAR Agency for Science Business Overview 11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.7.5 A*STAR Agency for Science Recent Developments 11.8 Technology and Research 11.8.1 Technology and Research Company Details 11.8.2 Technology and Research Business Overview 11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.8.5 Technology and Research Recent Developments 11.9 A*STAR Institute of Microelectronics (IME) 11.9.1 A*STAR Institute of Microelectronics (IME) Company Details 11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview 11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments 11.10 A2A Pharmaceuticals 11.10.1 A2A Pharmaceuticals Company Details 11.10.2 A2A Pharmaceuticals Business Overview 11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.10.5 A2A Pharmaceuticals Recent Developments 11.11 Abbvie 11.11.1 Abbvie Company Details 11.11.2 Abbvie Business Overview 11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.11.5 Abbvie Recent Developments 11.12 AbCellera 11.12.1 AbCellera Company Details 11.12.2 AbCellera Business Overview 11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.12.5 AbCellera Recent Developments 11.13 ABL Bio 11.13.1 ABL Bio Company Details 11.13.2 ABL Bio Business Overview 11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.13.5 ABL Bio Recent Developments 11.14 Abpro 11.14.1 Abpro Company Details 11.14.2 Abpro Business Overview 11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.14.5 Abpro Recent Developments 11.15 Academy of Military Medical Sciences (China) 11.15.1 Academy of Military Medical Sciences (China) Company Details 11.15.2 Academy of Military Medical Sciences (China) Business Overview 11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.15.5 Academy of Military Medical Sciences (China) Recent Developments 11.16 Accellix 11.16.1 Accellix Company Details 11.16.2 Accellix Business Overview 11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.16.5 Accellix Recent Developments 11.17 Accord Healthcare 11.17.1 Accord Healthcare Company Details 11.17.2 Accord Healthcare Business Overview 11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.17.5 Accord Healthcare Recent Developments 11.18 AccuGenomics 11.18.1 AccuGenomics Company Details 11.18.2 AccuGenomics Business Overview 11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.18.5 AccuGenomics Recent Developments 11.19 ACEA Biosciences 11.19.1 ACEA Biosciences Company Details 11.19.2 ACEA Biosciences Business Overview 11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.19.5 ACEA Biosciences Recent Developments 11.20 AC Immune 11.20.1 AC Immune Company Details 11.20.2 AC Immune Business Overview 11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.20.5 AC Immune Recent Developments 11.21 Acoustic MedSystems 11.21.1 Acoustic MedSystems Company Details 11.21.2 Acoustic MedSystems Business Overview 11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.21.5 Acoustic MedSystems Recent Developments 11.22 Adaptimmune 11.22.1 Adaptimmune Company Details 11.22.2 Adaptimmune Business Overview 11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.22.5 Adaptimmune Recent Developments 11.23 Aduro BioTech 11.23.1 Aduro BioTech Company Details 11.23.2 Aduro BioTech Business Overview 11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.23.5 Aduro BioTech Recent Developments 11.24 Advaxis 11.24.1 Advaxis Company Details 11.24.2 Advaxis Business Overview 11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.24.5 Advaxis Recent Developments 11.25 Adventus Ventures 11.25.1 Adventus Ventures Company Details 11.25.2 Adventus Ventures Business Overview 11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.25.5 Adventus Ventures Recent Developments 11.26 Aerolase 11.26.1 Aerolase Company Details 11.26.2 Aerolase Business Overview 11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction 11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023) 11.26.5 Aerolase Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
QYResearch社の医療分野での最新刊レポート
本レポートと同じKEY WORD（diagnostics）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
